Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.

Halvorsen TO, Sundstrøm S, Fløtten Ø, Brustugun OT, Brunsvig P, Aasebø U, Bremnes RM, Kaasa S, Grønberg BH.

Acta Oncol. 2016 Nov;55(11):1349-1354. Epub 2016 Aug 23.

PMID:
27549509
2.

Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.

Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S; Norwegian Lung Cancer Study Group.

Acta Oncol. 2016 May;55(5):591-7. doi: 10.3109/0284186X.2015.1092584. Epub 2015 Oct 23.

PMID:
26494411
3.

Low oxygen saturation and mortality in an adult cohort: the Tromsø study.

Vold ML, Aasebø U, Wilsgaard T, Melbye H.

BMC Pulm Med. 2015 Feb 12;15:9. doi: 10.1186/s12890-015-0003-5.

4.

How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial.

Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Aasebø U.

Clin Lung Cancer. 2015 May;16(3):183-92. doi: 10.1016/j.cllc.2014.08.005. Epub 2014 Nov 13.

5.

Low FEV1, smoking history, and obesity are factors associated with oxygen saturation decrease in an adult population cohort.

Vold ML, Aasebø U, Melbye H.

Int J Chron Obstruct Pulmon Dis. 2014 Oct 21;9:1225-33. doi: 10.2147/COPD.S69438. eCollection 2014.

6.

Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial.

Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Aasebø U.

J Thorac Oncol. 2014 Jun;9(6):825-33. doi: 10.1097/JTO.0000000000000184.

7.

Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.

Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Fløtten O, Aasebø U.

Br J Cancer. 2013 Sep 17;109(6):1467-75. doi: 10.1038/bjc.2013.466. Epub 2013 Aug 20.

8.

Predictors of oxygen saturation ≤95% in a cross-sectional population based survey.

Vold ML, Aasebø U, Hjalmarsen A, Melbye H.

Respir Med. 2012 Nov;106(11):1551-8. doi: 10.1016/j.rmed.2012.06.016. Epub 2012 Jul 13.

9.

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group.

Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C.

Br J Cancer. 2012 Jul 24;107(3):442-7. doi: 10.1038/bjc.2012.284. Epub 2012 Jul 3.

10.

The Lean method as a clinical pathway facilitator in patients with lung cancer.

Aasebø U, Strøm HH, Postmyr M.

Clin Respir J. 2012 Jul;6(3):169-74. doi: 10.1111/j.1752-699X.2011.00271.x. Epub 2011 Nov 15.

PMID:
21951490
11.
12.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S.

J Clin Oncol. 2009 Jul 1;27(19):3217-24. doi: 10.1200/JCO.2008.20.9114. Epub 2009 May 11.

PMID:
19433683
13.

Pulmonary function in long-term survivors of testicular cancer.

Haugnes HS, Aass N, Fosså SD, Dahl O, Brydøy M, Aasebø U, Wilsgaard T, Bremnes RM.

J Clin Oncol. 2009 Jun 10;27(17):2779-86. doi: 10.1200/JCO.2008.18.5181. Epub 2009 May 4.

PMID:
19414680
14.

Chemotherapy and quality of life in NSCLC PS 2 patients.

Helbekkmo N, Strøm HH, Sundstrøm SH, Aasebø U, Von Plessen C, Bremnes RM; Norwegian Lung Cancer Study Group.

Acta Oncol. 2009;48(7):1019-25. doi: 10.1080/02841860902795240.

PMID:
19274496
15.

Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.

Hermes A, Bergman B, Bremnes R, Ek L, Fluge S, Sederholm C, Sundstrøm S, Thaning L, Vilsvik J, Aasebø U, Sörenson S.

J Clin Oncol. 2008 Sep 10;26(26):4261-7. doi: 10.1200/JCO.2007.15.7545.

PMID:
18779613
16.

A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.

Grønberg BH, Bremnes RM, Aasebø U, Brunsvig P, Fløtten O, Amundsen T, von Plessen C, Wang M, Sundstrøm S; Norwegian Lung Cancer Study Group.

Lung Cancer. 2009 Jan;63(1):88-93. doi: 10.1016/j.lungcan.2008.04.003. Epub 2008 Jun 6.

PMID:
18538889
17.

Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy.

Helbekkmo N, Aasebø U, Sundstrøm SH, von Plessen C, Brunsvig PF, Bremnes RM; Norwegian Lung Cancer Study Group.

Lung Cancer. 2008 Nov;62(2):253-60. doi: 10.1016/j.lungcan.2008.03.003. Epub 2008 Apr 15.

PMID:
18417246
18.

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.

Helbekkmo N, Sundstrøm SH, Aasebø U, Brunsvig PF, von Plessen C, Hjelde HH, Garpestad OK, Bailey A, Bremnes RM; Norwegian Lung Cancer Study Group.

Br J Cancer. 2007 Aug 6;97(3):283-9. Epub 2007 Jun 26.

19.

Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy?

Sundstrøm S, Bremnes RM, Brunsvig P, Aasebø U, Kaasa S; Norwegian Lung Cancer Study Group.

J Thorac Oncol. 2006 Oct;1(8):816-24.

20.

Reduced pulmonary function is associated with lower levels of endogenous total and free testosterone. The Tromsø study.

Svartberg J, Schirmer H, Medbø A, Melbye H, Aasebø U.

Eur J Epidemiol. 2007;22(2):107-12. Epub 2007 Jan 27.

PMID:
17260104
21.

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.

von Plessen C, Bergman B, Andresen O, Bremnes RM, Sundstrom S, Gilleryd M, Stephens R, Vilsvik J, Aasebo U, Sorenson S.

Br J Cancer. 2006 Oct 23;95(8):966-73. Epub 2006 Oct 3.

22.

Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study.

Sundstrøm S, Bremnes R, Brunsvig P, Aasebø U, Olbjørn K, Fayers PM, Kaasa S; Norwegian Lung Cancer Study Group.

Radiother Oncol. 2005 May;75(2):141-8.

PMID:
16094739
23.
24.

Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial.

Svartberg J, Aasebø U, Hjalmarsen A, Sundsfjord J, Jorde R.

Respir Med. 2004 Sep;98(9):906-13.

25.

Pancreatic polypeptide is increased in patients with advanced malignant disease.

Hjalmarsen A, Bremnes RM, Aasebø U, Jorde R.

Anticancer Res. 2004 Jul-Aug;24(4):2515-7.

26.

[Surgical treatment of lung cancer].

Myrmel T, Dahl PE, Aasebø U, Bremnes R.

Tidsskr Nor Laegeforen. 2004 Apr 1;124(7):982; author reply 982-3. Norwegian. No abstract available.

27.

Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.

Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S.

J Clin Oncol. 2004 Mar 1;22(5):801-10.

PMID:
14990635
28.

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up.

Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S; Norweigian Lung Cancer Study Group.

Lung Cancer. 2003 Mar;39(3):303-13.

PMID:
12609569
29.

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group.

J Clin Oncol. 2002 Dec 15;20(24):4665-72.

PMID:
12488411
30.

[Lung cancer--a low status disease?].

Bremnes RM, Aasebø U.

Tidsskr Nor Laegeforen. 2002 Sep 30;122(23):2257. Norwegian. No abstract available.

31.

Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer.

Bremnes RM, Sundstrøm S, Vilsvik J, Aasebø U; Norwegian Lung Cancer Study Group.

J Clin Oncol. 2001 Aug 1;19(15):3532-8.

PMID:
11481360
32.

[Lung cancer].

Sundstrøm S, Aasebø U, Bremnes R.

Tidsskr Nor Laegeforen. 2001 Feb 10;121(4):406. Norwegian. No abstract available.

33.

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, Parisi A, Pham Tran N, Olivares R, Berille J.

Lung Cancer. 2000 Mar;27(3):145-57.

PMID:
10699688
34.

[Intrapleural fibrinolysis with streptokinase in th treatment of loculated empyema].

Aasebø U, Helbekkmo N.

Tidsskr Nor Laegeforen. 1999 Aug 20;119(19):2812-4. Norwegian.

PMID:
10494200
35.

Mitoxantrone in malignant pericardial effusion.

Norum J, Lunde P, Aasebø U, Himmelmann A.

J Chemother. 1998 Oct;10(5):399-404.

PMID:
9822359
36.

[Decentralized special training in pulmonary medicine. A project using telemedicine].

Aasebø U, Opdahl R, Strøm HH, Arild E, Bach B.

Nord Med. 1998 Sep;113(7):237-9. Norwegian.

PMID:
9755622
37.

[Is treatment of lung cancer characterized by nihilism?].

Aasebø U, Bremnes R.

Tidsskr Nor Laegeforen. 1998 May 20;118(13):2056. Norwegian. No abstract available.

PMID:
9656793
38.

Magnetic resonance imaging of the thorax in the evaluation of asbestosis.

Bekkelund SI, Aasebø U, Pierre-Jerome C, Holmboe J.

Eur Respir J. 1998 Jan;11(1):194-7.

39.

Intrapleurally instilled mitoxantrone in metastatic pleural effusions: a phase II study.

Aasebø U, Norum J, Sager G, Slørdal L.

J Chemother. 1997 Apr;9(2):106-11.

PMID:
9176748
40.

Sex hormone responses in healthy men and male patients with chronic obstructive pulmonary disease during an oral glucose load.

Hjalmarsen A, Aasebø U, Aakvaag A, Jorde R.

Scand J Clin Lab Invest. 1996 Nov;56(7):635-40.

PMID:
8981659
41.
42.

Impaired glucose tolerance in patients with chronic hypoxic pulmonary disease.

Hjalmarsen A, Aasebø U, Birkeland K, Sager G, Jorde R.

Diabetes Metab. 1996 Feb;22(1):37-42.

PMID:
8697294
43.

[An answer to an inquiry on diffuse panbronchiolitis. Now it has found its way here!].

Naalsund A, Foerster A, Aasebø U, Kearney M, Boe J.

Lakartidningen. 1995 Aug 30;92(35):3119-21. Swedish.

PMID:
7658766
44.

Pulmonary function 3-13 months after pneumonectomy, lobectomy or bilobectomy for lung cancer.

Hjalmarsen A, Aasebø U, Lie M.

Scand J Thorac Cardiovasc Surg. 1995;29(2):71-4.

PMID:
8643929
45.

Intrapleural bleomycin in the treatment of chylothorax.

Norum J, Aasebø U.

J Chemother. 1994 Dec;6(6):427-30.

PMID:
7535348
46.

Pituitary-gonadal dysfunction in male patients with lung cancer. Association with serum inhibin levels.

Aasebø U, Bremnes RM, de Jong FH, Aakvaag A, Slørdal L.

Acta Oncol. 1994;33(2):177-80.

PMID:
8204272
47.

Reversal of sexual impotence in male patients with chronic obstructive pulmonary disease and hypoxemia with long-term oxygen therapy.

Aasebø U, Gyltnes A, Bremnes RM, Aakvaag A, Slørdal L.

J Steroid Biochem Mol Biol. 1993 Dec;46(6):799-803.

PMID:
8274414
49.

Symptomatic effect of inhaled fenoterol in acute bronchitis: a placebo-controlled double-blind study.

Melbye H, Aasebø U, Straume B.

Fam Pract. 1991 Sep;8(3):216-22.

PMID:
1959720
50.

Gonadal endocrine dysfunction in patients with lung cancer: relation to responsiveness to chemotherapy, respiratory function and performance status.

Aasebø U, Bremnes RM, Aakvaag A, Slørdal L.

J Steroid Biochem Mol Biol. 1991 Sep;39(3):375-80.

PMID:
1911428

Supplemental Content

Loading ...
Support Center